-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130

Benzinga·09/29/2026 11:52:38
语音播报
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.